

Amendments to the Claims:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Claims 1-54 (Cancelled).

Claim 55 (New): A process for preparing a pharmaceutical unit dose composition comprising 2 to 8 mg 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy] benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

- (i) preparing a first composition comprising 5 to 20% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier;
- (ii) admixing the first composition with at least one pharmaceutically acceptable carrier; and
- (iii) formulating the composition produced in step (ii) into said pharmaceutical unit dose composition.

Claim 56 (New): A process according to claim 55, wherein the pharmaceutical unit dose composition is a tablet.

Claim 57 (New): A process according to claim 55, wherein the first composition is in granular form.

Claim 58 (New): A process according to claim 55, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 59 (New): A process according to claim 55, wherein the first composition contains 15% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 60 (New): A process according to claim 57, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 61 (New): A process according to claim 55, wherein the first composition contains 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

Claim 62 (New): A process according to claim 61, wherein the first composition is in granular form.

Claim 63 (New): A process according to claim 62, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 64 (New): A process according to claim 55, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable salt.

Claim 65 (New): A process according to claim 64, wherein the salt is a maleate salt.

Claim 66 (New): A process according to claim 55, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable solvate.

Claim 67 (New): A process according to claim 66, wherein the solvate is a hydrate.

Claim 68 (New): A process according to claim 55, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.

Claim 69 (New): A process according to claim 55, wherein the pharmaceutical unit dose composition comprises 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 70 (New): A process according to claim 55, wherein the pharmaceutical unit dose composition comprises 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 71 (New): A process according to claim 55, wherein the pharmaceutical unit dose composition comprises 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 72 (New): A pharmaceutical composition formed by the process of claim 55.

Claim 73 (New): A pharmaceutical composition formed by the process of claim 63.

Claim 74 (New): A pharmaceutical composition formed by the process of claim 65.

Claim 75 (New): A process for preparing a pharmaceutical unit dose composition comprising 1 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier, which process comprises:

- (i) preparing a first composition comprising 5 to 20% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form and a pharmaceutically acceptable carrier;
- (ii) admixing the first composition with at least one pharmaceutically acceptable carrier; and
- (iii) formulating the composition produced in step (ii) into said pharmaceutical unit dose composition.

Claim 76 (New): A process according to claim 75, wherein the pharmaceutical unit dose composition is a tablet.

Claim 77 (New): A process according to claim 75, wherein the first composition is in granular form.

Claim 78 (New): A process according to claim 75, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 79 (New): A process according to claim 77, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 80 (New): A process according to claim 75, wherein the first composition contains 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form, sodium starch glycollate, hydroxypropyl methylcellulose 2910, microcrystalline cellulose and lactose monohydrate.

Claim 81 (New): A process according to claim 80, wherein the first composition is in granular form.

Claim 82 (New): A process according to claim 81, wherein the first composition contains 10% by weight of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 83 (New): A process according to claim 75, wherein the pharmaceutically acceptable form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione is a pharmaceutically acceptable salt.

Claim 84 (New): A process according to claim 83, wherein the salt is a maleate salt.

Claim 85 (New): A process according to claim 75, wherein the pharmaceutical unit dose composition comprises 1 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione in a pharmaceutically acceptable form.

Claim 86 (New): A pharmaceutical composition formed by the process of claim 75.

Claim 87 (New): A pharmaceutical composition formed by the process of claim 82.

Claim 88 (New): A pharmaceutical composition formed by the process of claim 84.